公开(公告)号：US20240309030A1

公开(公告)日：2024-09-19

申请号：US18264986

申请日：2022-02-10

申请人： SHANGHAI SENHUI MEDICINE CO., LTD ,  SHANGHAI SHENGDI PHARMACEUTICAL CO., LTD ,  JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

发明人： Lingjian ZHU ,  Jianyu SHI ,  Changjin JI ,  Bangjie DONG ,  Jian HUANG

IPC分类号： C07F9/553 ,  A61K31/55 ,  A61K31/675 ,  C07D223/16

CPC分类号： C07F9/5535 ,  A61K31/55 ,  A61K31/675 ,  C07D223/16

摘要： Benzazepine compounds, a preparation method therefor and pharmaceutical use thereof. Specifically, the present invention relates to a compound represented by formula II-1 or formula VIII-1, a pharmaceutical composition containing same, and pharmaceutical use thereof. The benzazepine compounds can be used for treating diseases associated with vasopressin receptors, in particular hypertension, heart disease, etc.

公开(公告)号：US20240299572A1

公开(公告)日：2024-09-12

申请号：US18560986

申请日：2022-05-19

申请人： SHANGHAI DE NOVO PHARMATECH CO., LTD.

发明人： Zhaolong TONG ,  Man ZHANG ,  Heping YANG ,  Xiaohuan LIU ,  Longsheng WANG ,  Jicheng REN ,  Daxin GAO

IPC分类号： A61K47/68 ,  A61K47/54 ,  A61K47/65 ,  A61P35/00 ,  C07D223/16 ,  C07D401/12 ,  C07D471/04 ,  C07D519/00

CPC分类号： A61K47/6803 ,  A61K47/545 ,  A61K47/65 ,  A61K47/6851 ,  A61P35/00 ,  C07D223/16 ,  C07D401/12 ,  C07D471/04 ,  C07D519/00

摘要： The present application relates to a nitrogen-containing compound, a conjugate containing said compound, and an application thereof. Specifically, the present application provides a compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of a pharmaceutically acceptable salt thereof. The nitrogen-containing compound has a good regulating effect on TLR8 and can effectively treat, alleviate, and/or prevent various diseases caused by immunosuppression, such as a cancer or a viral infection.

公开(公告)号：US20230055376A1

公开(公告)日：2023-02-23

申请号：US17837622

申请日：2022-06-10

申请人： Arena Pharmaceuticals, Inc.

发明人： Juerg Lehmann ,  Konrad Feichtinger ,  Albert S. Ren ,  Graeme Semple

IPC分类号： A61K31/55 ,  C07D223/16 ,  C07D223/32 ,  C07D491/052 ,  A61P25/32 ,  A61P3/04 ,  A61P3/10 ,  A61P25/08

摘要： Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

公开(公告)号：US20220315537A1

公开(公告)日：2022-10-06

申请号：US17618729

申请日：2020-06-12

申请人： Bolt Biotherapeutics, Inc.

发明人： Shelley Erin Ackerman ,  Michael N. Alonso ,  Romas Kudirka ,  Arthur Lee ,  Brian Safina ,  Matthew Zhou

IPC分类号： C07D223/16 ,  C07H15/203 ,  C07D403/10 ,  C07D403/12

摘要： The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.

公开(公告)号：US11279681B2

公开(公告)日：2022-03-22

申请号：US17031814

申请日：2020-09-24

申请人： Valo Health, Inc.

发明人： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  David S. Millan ,  Matthew W. Martin ,  Kenneth W. Bair

IPC分类号： A61K31/55 ,  A61K31/554 ,  C07D223/16 ,  C07D281/02 ,  C07D281/10 ,  C07D471/04 ,  C07D513/04 ,  C07D267/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/04 ,  C07D267/12 ,  C07D243/14 ,  C07D291/08 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/14 ,  C07D417/04 ,  C07D498/04 ,  C07D498/08 ,  C07D493/08 ,  C07D413/08 ,  C07D491/107 ,  C07D495/10

摘要： The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US11203600B2

公开(公告)日：2021-12-21

申请号：US16684340

申请日：2019-11-14

申请人： Denali Therapeutics Inc.

发明人： Javier De Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian Fox ,  Cinzia Maria Francini ,  Christopher R. H. Hale ,  Cheng Hu ,  Colin Philip Leslie ,  Maksim Osipov ,  Elena Serra ,  Zachary K. Sweeney ,  Arun Thottumkara

IPC分类号： A61K31/553 ,  A61P43/00 ,  C07D498/04 ,  C07D223/16 ,  C07D267/04 ,  C07D267/14 ,  C07D413/14 ,  C07D519/00

摘要： The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

公开(公告)号：US20210276957A1

公开(公告)日：2021-09-09

申请号：US17254565

申请日：2019-06-20

申请人： TAIWANJ PHARMACEUTICALS CO., LTD.

发明人： Syaulan S. YANG ,  Kuang Yuan LEE ,  Meng Hsien LIU ,  Yan-Feng JIANG ,  Yu-Shiou FAN ,  Chiung Wen WANG ,  Mei-Chi HSU

IPC分类号： C07D223/16 ,  C07D215/26 ,  C07D401/10 ,  C07D409/04 ,  C07D491/056 ,  C07D495/04

摘要： The present disclosure relates to a compound of Formula I, or a geometric isomer, enantiomer, diastereomer, racemate, atropisomer, pharmaceutically acceptable salt, prodrug or solvate thereof. The present disclosure further relates to a composition comprising the compound of Formula (I). The compound and the composition described herein can be used to inhibit NADPH oxidase activity.

公开(公告)号：US10889570B2

公开(公告)日：2021-01-12

申请号：US16480842

申请日：2018-06-29

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： Keizo Kan ,  Masatoshi Takuwa ,  Hirotaka Tanaka ,  Hideto Fujiwara ,  Hokuto Yamabe ,  Satoshi Matsuda ,  Kazuhiro Ohdachi ,  Taiki Hanari ,  Yasuhiro Menjo ,  Tatsuya Urushima ,  Shigekazu Fujita

IPC分类号： A61K31/55 ,  A61P13/12 ,  C07D223/16 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/12 ,  C07D409/12

摘要： The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof.
In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is —C(═O)—NH—, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.

公开(公告)号：US10696655B2

公开(公告)日：2020-06-30

申请号：US16198597

申请日：2018-11-21

申请人： GENENTECH, INC. ,  CONSTELLATION PHARMACEUTICALS, INC.

发明人： Patrick Cyr ,  Sarah Bronner ,  F. Anthony Romero ,  Steven Magnuson ,  Vickie Hsiao-Wei Tsui ,  John Wai ,  Kwong Wah Lai ,  Fei Wang

IPC分类号： C07D223/16 ,  C07D243/12 ,  C07D243/14 ,  C07D267/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/04 ,  C07D417/14 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D413/10 ,  A61K31/435 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5513 ,  A61K45/06 ,  C07D487/22

摘要： The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

公开(公告)号：US20200024276A1

公开(公告)日：2020-01-23

申请号：US16563131

申请日：2019-09-06

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

发明人： Cara B. GONZALES ,  Stanton McHARDY

IPC分类号： C07D471/04 ,  C07D209/44 ,  C07C233/29 ,  A61K31/17 ,  C07C335/12 ,  C07C275/24 ,  C07D213/68 ,  C07D223/16 ,  C07D217/06 ,  A61K31/55 ,  A61K31/5377 ,  A61K31/4745 ,  A61K31/472 ,  A61K31/4035 ,  A61K31/165 ,  A61K31/155 ,  A61P35/00 ,  C07C211/29 ,  A61K45/06

摘要： The present disclosure relates generally to derivatives of capsazepine and methods of use thereof. In some aspects, the present disclosure relates to using capsazepine derivatives to treat cancer or other hyperproliferative diseases.